Radiosurgery system begins UK trials
This article was originally published in Clinica
Executive Summary
Trials of a new system for delivering low-energy radiation therapy directly to tumours have begun in the UK following successful Phase I trials in the US. The Photon Radiosurgery System (PRS), developed by US company Photoelectron, comprises a 3 mm-diameter, 100 mm-long needle which is inserted into the tumour, delivering X-rays from a battery-powered source. Initially configured for treating brain tumours, the system works with a stereotactic frame and the needle is passed through the track left by a biopsy cannula.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.